An evaluation of antibodies and clinical resistance to salmon calcitonin
AUTOR(ES)
Singer, Frederick R.
RESUMO
21 patients with Paget's disease of bone and one with osteoporosis were studied to detect development of antibodies to salmon calcitonin during chronic therapy. Antibody titers ranged from 1:40 to 1:30,000 in plasma obtained after treatment of 11 patients. Radio-immunoelectrophoresis revealed that the antibodies were restricted to the γG class. One patient, W. O., with Paget's disease initially responded to treatment with a decrease in bone turnover, but later became resistant to the hormone in association with the appearance of a very high titer (1:30,000) of antibody against salmon calcitonin. A 1:10 dilution of his plasma was shown to completely inactivate 20 mMRC units/ml of salmon calcitonin as detected by bioassay in rats; slight inactivation was detected at a 1:200 dilution. All other patients continued to respond to salmon calcitonin despite the development of antibody to the hormone in ten cases. No evidence of systemic allergic reactions or other toxicity was found in any patient. The data suggest that although antibody formation may occur in as many as 50% of patients treated with salmon calcitonin, this antibody response is unlikely to be of clinical significance in most patients. However, in an occasional patient, a marked antibody response may occur which interferes with the therapeutic use of the hormone.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=292399Documentos Relacionados
- Preparation, characterization, and in vivo evaluation of salmon calcitonin microspheres
- Calcitonin Resistance: Clinical and Immunologic Studies in Subjects with Paget's Disease of Bone Treated with Porcine and Salmon Calcitonins
- Preparation and Characterization of Salmon Calcitonin–biotin Conjugates
- AMINO ACID SEQUENCE OF SALMON ULTIMOBRANCHIAL CALCITONIN
- Phosphatydylglycerol promotes bilayer insertion of salmon calcitonin.